Risks of counterfeiting, diversion, product tampering, and other illegal activities continue to threaten pharmaceutical brands around the world. Technologies to combat these risks have steadily advanced, but many pharmaceutical executives still have questions, and some may have no brand protection strategy in place.
In the whitepaper, “9 Frequently Asked Questions about Pharmaceutical Brand Protection,” we address some of the common questions and offer some insights provided by CCL Industries. A few of these questions include:
Can I fight both counterfeiting and diversion risks with one approach?
I am not sure we can afford brand protection. How do we fit it in?
How do we assess whether our brand protection strategy is working?
Whatever your brand protection approach, it needs to include a vigilant strategy for monitoring unauthorized activity and evaluating ongoing and emerging risks, according to the company.
To learn more, please download the free whitepaper, 9 Frequently Asked Questions about Pharmaceutical Brand Protection, Answered, today!